|Bid||2.2100 x 4000|
|Ask||2.2200 x 1400|
|Day's Range||2.1800 - 2.3100|
|52 Week Range||1.1200 - 2.9100|
|Beta (5Y Monthly)||2.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.20|
Companies in the news are: MYOV, ITRM, COTY, OPK
OPKO Health (OPK) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Details the CEO buys this week for the following companies: OPKO Health, Orion Engineered Carbons SA and Inari Medical Continue reading...
In the current session, OPKO Health Inc. (NASDAQ: OPK) is trading at $2.42, after a 6.14% increase. Over the past month, the stock increased by 5.22%, and in the past year, by 22.22%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently down from its 52 week high by 16.84%.The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.OPKO Health Inc. has a lower P/E than the aggregate P/E of 87.79 of the diagnostics & research industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * Price Over Earnings Overview: Coty * Recap: Mesa Laboratories Q4 Earnings * Recap: Thermon Group Q4 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
OPKO Health, Inc. (OPK) today announced that the U.S. Food and Drug Administration (FDA) has authorized OPKO to undertake a Phase 2 trial with RAYALDEE® as a treatment for patients with mild-to-moderate COVID-19. The trial, entitled “A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of RAYALDEE (calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2 (REsCue),” is estimated to enroll 166 subjects, including many with stage 3 or 4 chronic kidney disease (CKD). The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up.
OPKO Health (OPK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
MIAMI, May 27, 2020 -- OPKO Health, Inc. (NASDAQ: OPK) announced today that management will be participating in the Jefferies Virtual Healthcare Conference being held June.
OPKO Health, Inc. (OPK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
OPKO Health's (OPK) subsidiary, BioReference Laboratories collaborates with MagnaCare to offer antibody testing to Labor groups in New York metropolitan area.
MagnaCare today announced a collaboration with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), to bring COVID-19 antibody testing to their Labor clients in the New York metropolitan area. Through this collaboration with BioReference, MagnaCare will offer on-site antibody blood testing to Labor members, delivering valuable information as the city, employers and individuals plan return-to-work strategies.
After announcing it has launched a COVID-19 screening program to help employers make return-to-work decisions for employees, OPKO Health (NASDAQ: OPK) saw its shares close the day up more than 10% on Thursday. OPKO Health's BioReference Labs has been assisting healthcare providers with COVID-19 testing services since mid-March. On Monday, management expanded its COVID-19 product platform with the launch of an antibody test that can determine if someone has been exposed to the virus, and on Wednesday, the healthcare company unveiled services designed to inform business decisions relating to employees.
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today launched the BioReference Employer Solution, a COVID-19 screening program that assists employers' decisions about return-to-work policies.
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a strategic collaboration with the Westchester Medical Center Health Network (WMCHealth), a 1,700-bed healthcare system headquartered in Valhalla, New York, to provide full laboratory administrative services, laboratory operations, reference testing and outpatient laboratory services.
Details the CEO buys this past week for the following companies: The GEO Group, AGNC Investment, Illinois Tool Works, Owl Rock Capital and OPKO Health Continue reading...
Its BioReference subsidiary is rolling out testing with five locations -- one in each of NYC's boroughs -- but will quickly expand its footprint.
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the launch of COVID-19 antibody screening available to New York City residents in partnership with New York City Health and Hospital Corporation (NYC Health + Hospitals). Testing will initially be performed for 140,000 residents at five locations across all five boroughs, with more testing sites to open in the next several weeks. Test results will be available through BioReference's Patient Portal, accessible by smartphone, tablet, desktop or traditional US Mail and become available within 1-3 days, on average.
What happened After reporting a year-over-year decline in revenue that was worse than industry watchers expected, OPKO Health (NASDAQ: OPK) saw its shares fall 16.7% on Thursday. So what Although the healthcare company is benefiting from significant demand for COVID-19 tests, rising demand in the final weeks of the first quarter wasn't enough to offset declining demand for lab services caused by widespread shelter-in-place orders that reduced visits to primary- and specialty-care doctors.